Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Diabetes in Developing Countries
Published in: International Journal of Diabetes in Developing Countries 1/2016

01-03-2016 | Original Article

Acute phase proteins and diabetes microvascular complications

Authors: Laily Najafi, Mojtaba Malek, Ameneh Ebrahim Valojerdi, Mohammad E. Khamseh

Published in: International Journal of Diabetes in Developing Countries | Issue 1/2016

Login to get access

Abstract

The association of serum high-sensitivity C-reactive protein and ferritin with diabetes microvascular complications has not been examined concurrently in people with type 2 diabetes. So, we carried out this study in order to investigate this association in a group of type 2 diabetic patients. In a prospective cross-sectional study, 242 people with type 2 diabetes were enrolled. All of the participants were evaluated for diabetes microvascular complications. Retinal status was evaluated by retinal color photography and indirect ophthalmoscopy exam with dilated pupils. Michigan neuropathy screening instrument was used for detection of peripheral neuropathy, and albumin/creatinine ratio in a spot urine sample was considered to diagnose diabetic nephropathy. High-sensitivity C-reactive protein and ferritin were measured as indicators of acute phase proteins. The mean for high-sensitivity C-reactive protein was 5.3 ± 13.02 mg/L, and for ferritin was 126.9 ± 114.4 ng/mL. Statistically significant difference was found between the high-sensitivity C-reactive protein levels and diabetic nephropathy. Spearman’s correlation coefficients test revealed that high-sensitivity C-reactive protein was positively correlated with diabetic nephropathy (P = 0.05, r = 0.14). However, such a correlation was not found for diabetic neuropathy and retinopathy. Using binary logistic regression analysis, a significant odds ratio was defined for nephropathy and high-sensitivity C-reactive protein level (OR = 2.62; CI = 1.13–6.06; P = 0.025). Our findings suggest that low-grade inflammation is an independent predictor of diabetic nephropathy and measurement of high-sensitivity C-reactive protein can be useful for early detection of high-risk individuals.
Literature
1.
Singh R, Shaw J, Zimmet P. Epidemiology of childhood type 2 diabetes in the developing world. Pediatr Diabetes. 2004;5:154–68.CrossRefPubMed
2.
King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79:1527–34.CrossRefPubMed
3.
Tsunoda K, Arita M, Yukawa M, et al. Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in type 2 diabetic patients. J Diabet Complications. 2005;19(3):123–7.CrossRef
4.
Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7(2):169–77.CrossRefPubMed
5.
Kang ES, Kim HJ, Ahn CW, et al. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2005;69(2):151–9.CrossRefPubMed
6.
Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle aged men: results from the MONICA Augsburg Cohort Study. Arch Intern Med. 2003;163:93–9.CrossRefPubMed
7.
Wang Z, Hoy WE. C-reactive protein and the risk of developing type 2 diabetes in Aboriginal Australians. Diabetes Res Clin Pract. 2007;76(1):37–43.CrossRefPubMed
8.
Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc. 2001;286:327–34.CrossRef
9.
Nakanishi S, Yamane K, Kamei N, et al. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003;26:2754–7.CrossRefPubMed
10.
Laaksonen DE, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47:1403–10.CrossRefPubMed
11.
Yamada S, Gotoh T, Nakashima Y, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol. 2001;153:1183–90.CrossRefPubMed
12.
Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol. 2000;20:1052–6.CrossRefPubMed
13.
Ong D, Wang L, Zhu Y, et al. The response of ferritin to LPS and acute phase of Pseudomonas infection. J Endotoxin Res. 2005;11(5):267–80.CrossRefPubMed
14.
Larade K, Storey KB. Accumulation and translation of ferritin heavy chain transcripts following anoxia exposure in a marine invertebrate. J Exp Biol. 2004;207(8):1353.CrossRefPubMed
15.
Beck G, Ellis TW, Habicht GS, et al. Evolution of the acute phase response: iron release by echinoderm (Asterias forbesi) coelomocytes, and cloning of an echinoderm ferritin molecule. Dev Comp Immunol. 2002;26(1):11–26.CrossRefPubMed
16.
Bottke W, Burschyk M, Volmer J. On the origin of the yolk protein ferritin in snails. Rouxs Arch Dev Biol. 1988;197(7):377.CrossRef
17.
Liao L, Lei MX, Chen HL, et al. High-sensitive C-reactive protein and type 2 diabetic nephropathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2004;29(6):627–30.PubMed
18.
Oba K, Yamashita N, Okazaki K, et al. High levels of serum ferritin in elderly patients with non-insulin-dependent diabetes mellitus. Nihon Ronen Igakkai Zasshi. 1997;34(4):305–11.CrossRefPubMed
19.
Canturk Z, Cetinarslan B, Tarkun I, et al. Serum ferritin levels in poorly- and well-controlled diabetes mellitus. Endocr Res. 2003;29(3):299–306.CrossRefPubMed
20.
Xu-biao M, Zhi-ming W, Di-ming Z. Relationship between serum ferritin and diabetic nephropathy. Chin J Lab Diagn. 2009;12.
21.
Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the Modified Airlie House Classification. ETDRS report number 10. Ophthalmology. 1991;98:786–806.CrossRef
22.
23.
Inoue K, Kato S, Ohara C, et al. Ocular and systemic factors relevant to diabetic keratoepitheliopathy. Cornea. 2001;20(8):798–801.CrossRefPubMed
24.
Herpers BL, Endeman H, de Jong BAW, et al. Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes. Clin Exp Immunol. 2009;156(3):488–94.CrossRefPubMedPubMedCentral
25.
Nayak BS, Roberts L. Relationship between inflammatory markers, metabolic and anthropometric variables in the Caribbean type 2 diabetic patients with and without microvascular complications. J Inflamm. 2006;3:1–7.CrossRef
26.
Schalkwijk CG, Poland DC, Dijk WVD, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999;42:351–7.CrossRefPubMed
27.
Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463–524.CrossRefPubMed
28.
Ross R. The pathogenesis of atherosclerosis, a perspective for the 1990s. Nature. 1993;362:801–9.CrossRefPubMed
29.
Amanullah S, Jarari A, Govindan M, et al. Association of hs-CRP with diabetic and non-diabetic individuals. Jordan J Biol Sci. 2010;3(1):7–12.
30.
Sitzer M, Markus HS, Mendall MA, et al. C-reactive protein and carotid intimal medial thickness in a community population. J Cardiovasc Risk. 2002;9:97–103.CrossRefPubMed
31.
Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001;104:63–7.CrossRefPubMed
32.
Sesmilo G, Biller BMK, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. Ann Intern Med. 2000;133(2):111–22.CrossRefPubMed
33.
Smith JF, Dykes R, Douglas JE, et al. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA. 1999;281:1722–7.CrossRefPubMed
34.
Ridker P, Cushman M, Stampfer M, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9.CrossRefPubMed
35.
Takeda T, Hoshida S, Nishino M, et al. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis. 2003;169:155–8.CrossRefPubMed
36.
Del Cañizo Gómez FJ, Fernández Pérez C, Moreno Ruiz I, et al. Microvascular complications and risk factors in patients with type 2 diabetes. Endocrinol Nutr. 2011;58(4):163–8.CrossRefPubMed
37.
Yokoyama H, Jensen J, Myrup B, et al. Raised serum sialic acid concentration precedes onset of microalbuminuria in IDDM. Diabetes Care. 1996;19:435–40.CrossRefPubMed
38.
39.
Mojahedi MJ, Bonakdaran S, Hami M, et al. Elevated serum C-reactive protein level and microalbuminuria in patients with type 2 diabetes mellitus. Iran J KidneyDis. 2009;3:12–6.
40.
Lim LS, Tai ES, Mitchell P, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(9):4458–63.CrossRefPubMed
41.
Holm J, Ravn J, Ingemann Hansen S. Urinary excretion of alpha1-microglobulin and albumin in acute myocardial infarction. Correlation with plasma concentrations of troponin I and C-reactive protein. Scand J Urol Nephrol. 2006;40:339–44.CrossRefPubMed
42.
Brownlee M, Aiello LP, Friedman E, Vinik AI, Nesto Rw, Boulton AJ. Complications of diabetes mellitus. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Endocrinology. 10th ed. Philadelphia: WB Saunders; 2003. p. 1509–40.
43.
Ladeia AM, Stefanelli E, Ladeia-Frota C, et al. Association between elevated serum C-reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care. 2006;29:424–6.CrossRefPubMed
44.
Scheid DC, McCarthy LH, Lawler FH, et al. Screening for microalbuminuria to prevent nephropathy in patients with diabetes: a systematic review of the evidence. J Fam Pract. 2001;50:661–8.PubMed
45.
Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–9.CrossRefPubMed
46.
Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2094–9.CrossRefPubMed
47.
Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890–6.CrossRefPubMed
48.
Jager A, van Hinsbergh VW, Kostense PJ, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn Study. Diabetes. 2000;49:485–91.CrossRefPubMed
49.
Jager A, van Hinsbergh VW, Kostense PJ, et al. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:3071–8.CrossRefPubMed
50.
Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96:4219–25.CrossRefPubMed
51.
English P, Williams G. Type 2 diabetes. In Ann NY Acad Sci Volume 1067. London: Martin Dunitz Ltd; 2001. p. 448–453
52.
Schmiedel O, Schroeter ML, Harvey JN. Microalbuminuria in type 2 diabetes indicates impaired microvascular vasomotion and perfusion. Am J Physiol Heart Circ Physiol. 2007;293:H3424–31.CrossRefPubMed
53.
Hayden MR, Tyagi SC, Kolb L, et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol. 2005;4:4.CrossRefPubMedPubMedCentral
54.
Festa A, D’Agostino R, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int. 2000;58:1703–10.CrossRefPubMed
55.
Shelbaya S, Amer H, Seddik S, et al. Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients. Eur Rev Med Pharmacol Sci. 2012;16(2):176–82.PubMed
56.
Fu CC, Wu DA, Wang JH, et al. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients. Acta Diabetol. 2009;46(2):127–34.CrossRefPubMed
57.
Andreas F, Ralph D, George H, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects, the insulin resistance atherosclerosis study. Kidney Int. 2000;58:1703–10.CrossRef
58.
Pannacciulli N, Cantatore FP, Minenna A, et al. Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women. J Int Med. 2001;250:502–7.CrossRef
59.
Schram MT, Chaturvedi N, Schalkwijk CG, et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370–8.CrossRefPubMed
60.
Spijkerman AM, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diabet Med. 2007;24:969–76.CrossRefPubMed
61.
Van Hecke MV, Dekker JM, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48:1300–6.CrossRefPubMed
62.
Le DS, Miles R, Savage PJ, et al. The association of plasma fibrinogen concentration with diabetic microvascular complications in young adults with early-onset of type 2 diabetes. Diabetes Res Clin Pract. 2008;82:317–23.CrossRefPubMed
63.
Nguyen TT, Alibrahim E, Amirul IF, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32:1704–9.CrossRefPubMedPubMedCentral
64.
Klein BE, Knudtson MD, Tsai MY, et al. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2009;127:1175–82.CrossRefPubMedPubMedCentral
65.
Firkin F, Rush B. Interpretation of biochemical tests for iron deficiency: diagnostic difficulties related to limitations of individual tests. Aust Prescr. 1997;20:74–6.CrossRef
66.
Elis A, Ferencz JR, Gilady G, et al. Is serum ferritin high in patients with diabetic retinopathy? A controlled study. Endocr Res. 2004;30(2):141–7.CrossRefPubMed
67.
Eshed I, Elis A, Lishner M. Plasma ferritin and type 2 diabetes mellitus: a critical review. Endocr Res. 2001;27(1–2):91–7.CrossRefPubMed
68.
Khatana SAM, Taveira TH, Choudhary G, et al. Change in hemoglobin A1c and C-reactive protein levels in patients with diabetes mellitus. J Cardiometab Syndr. 2009;4(2):76–80.CrossRefPubMed
69.
Raj S, Rajan GV. Correlation between elevated serum ferritin and HbA1c in type 2 diabetes mellitus. Int J Res Med Sci. 2013;1(1):12–5.CrossRef
70.
Eschwege E, Saddi R, Wacjman H, et al. Haemoglobin A1c in patients on venesection therapy for haemochromatosis. Diabete Metab. 1982;8:137–40.PubMed
Metadata
Title
Acute phase proteins and diabetes microvascular complications
Authors
Laily Najafi
Mojtaba Malek
Ameneh Ebrahim Valojerdi
Mohammad E. Khamseh
Publication date
01-03-2016
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 1/2016
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-015-0389-x

Other articles of this Issue 1/2016

International Journal of Diabetes in Developing Countries 1/2016 Go to the issue

Original Article

Comparison of sulfur transferases in various tissue and mitochondria of rats with type 1 diabetes mellitus induced by streptozotocin

Original Article

CTLA-4 +49A/G gene polymorphism and type 1 diabetes mellitus in the Chinese population: a meta-analysis of 2238 subjects

Short Article

Helicobacter pylori infection in elderly Chinese patients with type 2 diabetes

Original Article

Clinical, molecular, and therapeutic aspects of NDM in ten cases with diabetes in 1st 6 months of life

Original Article

Expression of glucokinase, glucose 6-phosphatase, and stress protein in streptozotocin-induced diabetic rats treated with natural honey

Original Article

The association between urodynamic findings and micro-vascular complications in type 2 diabetic patients with or without voiding symptoms
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits